Cell4Cure AB, a cell therapy company for development of treatments for the inducing of immune tolerance. The proprietary technology platform is based on dendritic cells mediating antigen-specific tolerance for the prevention or cure of diseases where the immune system is the enemy. The first clinical study, “Toler8”, focused on inducing tolerance to FVIII, preventing the occurrence of FVIII inhibitors, neutralizing anti-bodies (Nabs), in hemophilia A patients.